Corcept Therapeutics ((CORT)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Corcept Therapeutics is conducting a study titled ‘Study of the Prevalence of Endogenous Hypercortisolism in Patients With Resistant Hypertension (MOMENTUM).’ The primary goal is to assess how common endogenous hypercortisolism (eHC) is among patients with resistant hypertension (rHTN). This study is significant as it could lead to better understanding and management of these conditions, potentially improving patient outcomes.
The study is non-interventional and involves administering a dexamethasone suppression test to identify eHC in patients. The purpose is to measure cortisol levels after taking dexamethasone, which helps in diagnosing eHC.
This observational study follows a cohort model with a cross-sectional time perspective. It involves approximately 1,000 patients across 45 sites in the United States. The study design does not include any allocation or masking, focusing solely on observational data collection.
The study began on March 28, 2025, with the latest update submitted on June 27, 2025. These dates are crucial as they mark the study’s progress and ensure transparency in its development.
The update from this study could influence Corcept Therapeutics’ stock performance by attracting investor interest due to its potential impact on the treatment of resistant hypertension. Understanding the prevalence of eHC can also provide a competitive edge in the pharmaceutical industry, potentially affecting market dynamics.
The study is currently recruiting, and further details are available on the ClinicalTrials portal.